CSS
AEGR

Cubist Systematic Strategies’s Aegerion Pharmaceuticals AEGR Stock Holding History

Cubist Systematic Strategies’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,905
Closed -$130K – 2167
2014
Q3 		$130K Sell
3,905
-13,173
-77% -$409K 0.01% 1495
2014
Q2 		$548K Buy
+17,078
New +$636K 0.03% 700

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Cubist Systematic Strategies's AEGR Position: Q4 2014 in Review

Cubist Systematic Strategies sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 3,905 shares — an estimated $130K sold.

Cubist Systematic Strategies first reported a position in AEGR in Q2 2014 and held it in 2 quarters. The position peaked at $548K in Q2 2014. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Cubist Systematic Strategies reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Cubist Systematic Strategies sold 3,905 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $130K.
  • Cubist Systematic Strategies first reported a position in Aegerion Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Cubist Systematic Strategies's Aegerion Pharmaceuticals position peaked at $548K in Q2 2014.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Cubist Systematic Strategies's 13F filing for Q4 2014, filed 17 Feb 2015.